25Apr 2017

ENHANCER OF ZESTE HOMOLOG 2 AND VASCULAR ENDOTHELIAL GROWTH FACTOR IMMUNOHISTOCHEMICAL EXPRESSION ARE ASSOCIATED WITH ADVERSE CLINICAL OUTCOME IN NON-METASTATIC CLEAR CELL RENAL CELL CARCINOMA.

  • Department of pathology, Faculty of Medicine, Zagazig University, Egypt.
  • Department of Medical Oncology, Faculty of Medicine, Zagazig University, Egypt.
  • Department of General surgery, Faculty of Medicine, Zagazig University, Egypt.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background: Clear cell renal cell carcinoma (CCRCC) represents the most common malignant adult renal tumor. Its poor prognosis is due to poor response to current treatment options. Identification of new therapeutic targets is a priority. Enhancer of zeste homolog 2 (EZH2) expression is associated with aggressive behavior in different cancers. Vascular endothelial growth factor (VEGF) is strong angiogenic agent that promotes angiogenesis during the growth of tumor. Aim: To assess the significance of immunohistochemical expression of EZ2H and VEGF on tumor behavior, prognosis and patient survival in clear cell renal cell carcinoma. Methods: Immunohistochemical expressions of EZH2, VEGF,Ki-67were evaluated in 25 cases of CCRCC, correlated with each other , with clinicopathological parameters and patients survival. Results: Expression of EZH2 was significantly correlated with tumor grade and stage (p< 0.001), metastasis to lymph node (p=0.016), Ki67 expression (p= 0.014) and with local recurrence of the tumor (p= 0.001) in CCRCC cases. Vascular Endothelial Growth Factor was significantly positively correlated with tumor grade and stage (p< 0.001), Ki67 expression (p= 0.008) and local recurrence of the tumor (p= 0.001) while no correlation was found with lymph node metastasis (p=0.096). Direct correlation was detected between EZH2 and VEGF expression (p< 0.001), and a significant positive correlation was detected between ki-67 and both EZH2 (p= 0.003), and VEGF (p<0.001).High EZH2 and VEGF expression was significantly positively correlated with worse 2-year overall survival (OS) (p < 0.001 and p= 0.009, respectively).Conclusion: EZH2 and VEGF can be considered as independent prognostic markers in CRCC and may be used as a target for therapy in these cases.

  1. Au S, Wong C, Lee J, Fan D, Tsang F, Ng L & Wong C. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology. 2012;56(2):622?631.
  2. Baldewijns M., Roskams, T., Ballet V., Van den Eynden G., Van Laere S., Van der Auwera I & Van Poppel H "A low frequency of lymph node metastasis in clear‐cell renal cell carcinoma is related to low lymphangiogenic activity." BJU international 103, no. 12 (2009): 1626-1631.
  3. Bracken A, Pasini D, Capra M, Prosperini E, Colli E, Helin K.EZH2 is downstream of the pRB-E2F pathway, essential forproliferation and amplified in cancer. EMBO J 2003; 22: 5323?35.
  4. B?rgesser M, Riva V, Ojeda S, Mu?oz Morales D, Calafat P, Diller A. Expression of VEGF-A, HIF-1 A, CD34 and Ki67 in clear cell renal cell carcinomas and their relationship with conventional prognostic markers. Rev FacCien Med UnivNac Cordoba. 2014;71:7-15.
  5. Crea F, Paolicchi E, Marquez VE, Danesi R. Polycombgenesand cancer: Time for clinical application? Crit Rev OncolHematol 2012; 83: 184?93.
  6. Dang X, Ma A, Yang L,Het H, Shang T and Luo Y. MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. Cancer Genet 2012; 205: 113?23.
  7. Ding L, Erdmann C, Chinnaiyan AM, Merajver SD, Kleer CG: Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. Cancer Res 2006, 66(8):4095-4099.
  8. Ebru T, Fulya O, Hakan A, Vuslat Y, Necdet S, Nuray C & Filiz O. Analysis of various potential prognostic markers and survival data in clear cell renal cell carcinoma. International braz j urol: official journal of the Brazilian Society of Urology. (2016).
  9. Edge S. and Compton C. "The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM." Annals of surgical oncology 17, no. 6 (2010): 1471-1474.
  10. Eichelberg C, Junker K, Ljungberg B, Moch H: Diagnostic and Prognostic Molecular Markers for Renal Cell Carcinoma: A Critical Appraisal of the Current State of Research and Clinical Applicability. EurUrol 2009, 55(4):851-863.
  11. Fuhrman S, Lasky L, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma.Am J SurgPathol. 1982 Oct; 6(7):655-63.
  12. Gerdes J, Lemke H, Baisch J, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody HI 67. J Immunol 1984;133:1710-5. 20.
  13. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300. Erratum in: CA Cancer J 2011;61:133-4.
  14. Kim K. and Roberts C. Targeting EZH2 in cancer.Nature medicine, (2016).22(2), 128-134.
  15. Lainakis G and Bamias A."Targeting angiogenesis in renal cell carcinoma."Current cancer drug targets 8, no. 5 (2008): 349-358.
  16. Lampinem A, Virman J, Bono P Luukkaala T, Sunela K, Kujala P, Saharinen P, Kellokumpu-Lehtinen P. Novel angiogenesis markers as long term prognostic factors in patients with renal cell cancer. ClinGenitourin Cancer. 2016. doi: 10.1016/j.clgc.2016.07.008.
  17. Lee H. and Choe M. Expression of EZH2 in renal cell carcinoma as a novel prognostic marker.Pathology international, 2012.62(11), pp.735-741.
  18. Liu L, Xu Z, Zhong L, Wang H, Jiang S, Long Q, Xu J. and Guo J. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma. BJU Int. 2016; 117(2):351-62.
  19. Mehdi M, Nagi A, and Naseem N. "MCM-2 and Ki-67 as proliferation markers in renal cell carcinoma: A quantitative and semi-quantitative analysis." International braz j urol 42, no. 6 (2016): 1121-1128.
  20. Osman W and Youssef N. Combined use of COX-1 and VEGF immunohistochemistry refines the histopathologic prognosis of renal cell carcinoma. Int J ClinExpPathol. 2015; 8(7):8165-8177.
  21. Kocarslan S, Guldur M, ?Ekinci T, ?Ciftci H and? Ozardali H. Comparison of clinicopathological parameters with FoxM1 expression in renal cell carcinoma 2014. (10)?,1076-1081.
  22. Cheng S.H, Jia-Ming L, Qin-Yu L, De-Yi L, Bang-Hua L, Hong L, and Kun-Jie W. "Prognostic role of microvessel density in patients with renal cell carcinoma: a meta-analysis." Int J ClinExpPathol. 2014; 7(9): 5855?5863.
  23. Takawa M, Masuda K, Kunizaki M, Takagi K, Iwai Y, Cho H, Toyokawa G, Yamane Y, Maejima K. and Field H. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci 2011; 102: 1298?305.
  24. Testoni B, Schinzari V, Guerrieri F, Gerbal-Chaloin S, Blandino G, Levrero M. p53-paralog DNp73 oncogene is repressed by IFNalpha/STAT2 through the recruitment of the Ezh2 polycomb group transcriptional repressor. Oncogene 2011; 30: 2670?8.
  25. Tian Y, Hong M, Guo Q, Chen Z, Jing S, Ma B, and Wang Z. Clinicopathological and prognostic relevance of EZH2 expression in renal cell carcinoma: a meta-analysis. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, (2016).9(6), 9714-9724.
  26. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden JM, Bollen M, Esteller M, Di Croce L, de Launoit Y, Fuks F: The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006, 439(7078):871-874.
  27. Wagener N, Holland D, Bulkescher J, Crnković‐Mertens I, Hoppe‐Seyler K, Zentgraf H, Pritsch M, Buse S, Pfitzenmaier J, Haferkamp A. and Hohenfellner M. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apo- ptosis resistance in renal cell carcinoma cells. Int J Cancer 2008; 123: 1545?50.
  28. Wagener N, Macher-Goeppinger S, Pritsch, M, H?sing J, Hoppe-Seyler K., Schirmacher P& Hohenfellner M. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC cancer, .(2010) 10(1), 524.
  29. Wang Y, Chen Y, Geng H, Qi C, Liu Y. and Yue D. Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas. Tumor Biol. 2015; 36:7159-7166.
  30. Xu Z, Zhang B, Gao Y, Wan X, Zhang , Chen Y., Wang N., Sun, and Fu Y. "EZH2 promotes tumor progression by increasing VEGF expression in clear cell renal cell carcinoma." Clinical and Translational Oncology 17, no. 1 (2015): 41-49.
  31. Tian Y, Hong M, Guo Q, Chen Z, Jing S, Ma B,Wang H, Rodriguez R and Wang Z. Clinicopathological and prognostic relevance of EZH2 expression in renal cell carcinoma: a meta-analysis.Int J ClinExp Med. 2016; 9(6):9714-9724.
  32. Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, and Bray F. "International variations and trends in renal cell carcinoma incidence and mortality."European urology 67, no. 3 (2015): 519-530.

[Mona Mostafa Ahmed, Mai M. abdelwahab, Safa A. Balata and Hassan R Ashour. (2017); ENHANCER OF ZESTE HOMOLOG 2 AND VASCULAR ENDOTHELIAL GROWTH FACTOR IMMUNOHISTOCHEMICAL EXPRESSION ARE ASSOCIATED WITH ADVERSE CLINICAL OUTCOME IN NON-METASTATIC CLEAR CELL RENAL CELL CARCINOMA. Int. J. of Adv. Res. 5 (Apr). 1308-1322] (ISSN 2320-5407). www.journalijar.com

Mona Mostafa Ahmed
Lecturer of pthology ?Faculty of Medicine Zagazig University

DOI:

Article DOI: 10.21474/IJAR01/3949      
DOI URL: https://dx.doi.org/10.21474/IJAR01/3949

Download Full Paper

Download PDF No. of Downloads: 25 | No. of Views: 115